Celtaxsys to Present at Jefferies Healthcare and JMP Securities Life Sciences Conferences ATLANTA, GA--(Marketwired - May 23, 2016) -  Celtaxsys, Inc., a clinical stage pharmaceutical company focused on developing anti-inflammatory therapies for cystic fibrosis (CF) lung disease and...

Celtaxsys Begins EU Enrollment for CF Lung Function Preservation Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis ATLANTA, GA--(Marketwired - May 03, 2016) - Celtaxsys, a clinical stage drug development company focused on advancing therapies for patients with rare and orphan inflammatory diseases, announced...

Celtaxsys to Present at 27th Annual Piper Jaffray Healthcare Conference ATLANTA, GA--(Marketwired - December 01, 2015) - Celtaxsys, a clinical stage drug development company focused on advancing foundational medicine for patients suffering from orphan inflammatory...

Celtaxsys to Present Clinical Data on Oral Acebilustat at North American Cystic Fibrosis Conference: Key Inflammation Biomarkers Reduced in CF Patients ATLANTA, GA--(Marketwired - October 01, 2015) - Celtaxsys, a clinical stage drug development company focused on advancing care for patients suffering from orphan inflammatory diseases, announced today...